Hirotaka Miyashita

Also affiliated with University of Tsukuba, University of California San Diego, Dartmouth Psychiatric Research Center, Tsukuba Medical Center Hospital, Moores Cancer Center, Dartmouth Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy”.

Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0270

N/A

0.457DataRank · unranked

9 citations

Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro +6 more

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy

npj Genomic Medicine(2023)10.1038/s41525-023-00359-8

N/A

0DataRank · unranked

21 citations

Razelle Kurzrock, Nicholas Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla +8 more

Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity

Cancer Medicine(2023)10.1002/cam4.6844

N/A

0DataRank · unranked

13 citations

Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee +7 more

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy

Research Square(2023)10.21203/rs.3.rs-2551645/v1

N/A

0DataRank · unranked

2 citations

Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro +6 more

Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2614

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

ESMO Open(2024)10.1016/j.esmoop.2024.102942

N/A

0DataRank · unranked

31 citations

Razelle Kurzrock, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Mina Nikanjam +10 more

Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Journal of Cancer Immunology(2024)10.33696/cancerimmunol.6.086

N/A

0DataRank · unranked

12 citations

David S. Hong, Hirotaka Miyashita

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy

iScience(2024)10.1016/j.isci.2024.109632

N/A

0DataRank · unranked

10 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types

American Journal of Cancer Research(2024)10.62347/jrjp7877

N/A

0DataRank · unranked

7 citations

Hirotaka Miyashita

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists

Cancer Communications(2024)10.1002/cac2.12592

N/A

0DataRank · unranked

4 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +7 more

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.2626

N/A

0DataRank · unranked

1 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +5 more

Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Cancer Medicine(2025)10.1002/cam4.71467

N/A

0DataRank · unranked

5 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary Nesline +5 more

Tumor mutational burden, PD-1, negative Wnt/β-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2625

N/A

0DataRank · unranked

0 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary Nesline +6 more

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Cancer Medicine(2023)10.1002/cam4.6000

N/A

0DataRank · unranked

32 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee +7 more

Natural killer cell transcriptomic expression and prediction of survival after immune checkpoint blockade across cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2518

N/A

0DataRank · unranked

0 citations

Daisuke Nishizaki, Suzanna Lee, Taylor J. Jensen, Shumei Kato, Paul DePietro +3 more